Patient P-01393
Therapy response
Improving
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
90%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 No meaningful change — Dietary Support Protocol NP-02
- Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 54 GI-04 recommended — GI Support Protocol GI-04
- Day 55 Patient accepted — Started GI-04 in the companion
- Day 63 GI symptom burden −20% vs expected — GI Support Protocol GI-04
- Day 65 ME-01 recommended — Monitoring Escalation ME-01
- Day 66 Patient accepted — Started ME-01 in the companion
- Day 69 Tolerance state changed — Unstable → Improving
- Day 69 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 47.
Primary contributors, last 14 days
- GI instability+14
- Treatment adherence-7
- Inflammatory activity+6
- Nutritional resilience-6
- Toxicity+3
What helped?
- Dietary Support Protocol NP-02Day 31Result: no meaningful change
- GI Support Protocol GI-04Day 54Result: symptom burden −20%
- Monitoring Escalation ME-01Day 65Result: deterioration detected before clinical escalation
LIFE OS recommendation
Supportive Compound SC-12
68%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 81% showed improvement
- median effect visible after 6 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 59 and rising
- Inflammatory signalling ↑60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 59
- WearableHRV 23 ms, trending down
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 37/100
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↓45
- WearableResting HR 73 bpm
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 52
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.5 · butyrate capacity 37/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 26 ms
- Sleep
- 6.3 h
- Steps
- 5,991
- Resting HR
- 73 bpm
Daily log: GI score 59, nutritional resilience 38, adherence 49.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01462 | 62% | S14 | NP-02 | improved | 47 |
| P-01364 | 61% | S14 | GI-04 | improved | 49 |
| P-01496 | 60% | S14 | SC-12 | improved | 46 |
| P-01692 | 60% | S14 | NP-02 | improved | 49 |
| P-01879 | 57% | S14 | SC-12 | improved | 51 |
| P-01465 | 55% | S14 | NP-02 | improved | 56 |
| P-01433 | 54% | S14 | GI-04 | improved | 48 |
| P-01872 | 53% | S14 | NP-02 | improved | 47 |
| P-01573 | 52% | S14 | GI-04 | improved | 49 |
| P-01624 | 52% | S14 | GI-04 | improved | 52 |
| P-01647 | 52% | S14 | GI-04 | improved | 64 |
| P-01339 | 51% | S14 | GI-04 | improved | 54 |